Celularity (NASDAQ:CELU) and HUTCHMED (NASDAQ:HCM) Financial Survey

HUTCHMED (NASDAQ:HCM) and Celularity (NASDAQ:CELU) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

HUTCHMED has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for HUTCHMED and Celularity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1	3	1	0	2.00
Celularity	1	0	1	0	2.00

HUTCHMED currently has a consensus price target of $20.88, suggesting a potential upside of 30.06%. Celularity has a consensus price target of $6.00, suggesting a potential upside of 358.02%. Given Celularity’s higher probable upside, analysts plainly believe Celularity is more favorable than HUTCHMED.

Profitability

This table compares HUTCHMED and Celularity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Celularity	-198.75%	N/A	-65.03%

Valuation & Earnings

This table compares HUTCHMED and Celularity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$630.20 million	4.44	$37.73 million	N/A	N/A
Celularity	$54.22 million	0.69	-$57.89 million	($3.33)	-0.39

HUTCHMED has higher revenue and earnings than Celularity.

Summary

HUTCHMED beats Celularity on 5 of the 9 factors compared between the two stocks.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.